Active Biotech AB

ST:ACTI Sweden Biotechnology
Market Cap
$9.45 Million
Skr105.97 Million SEK
Market Cap Rank
#32594 Global
#507 in Sweden
Share Price
Skr0.04
Change (1 day)
-3.60%
52-Week Range
Skr0.04 - Skr0.34
All Time High
Skr28.53
About

Active Biotech AB (publ), a biotechnology company, engages in the research, development, and production of pharmaceutical products in Sweden. It is developing Tasquinimod, a small molecule immunomodulator, which is in Phase Ib/IIa clinical trial to treat relapsed refractory multiple myeloma; Laquinimod, a mechanism which is in phase 1 for the treatment of severe inflammatory eye diseases, such as… Read more

Active Biotech AB (ACTI) - Total Liabilities

Latest total liabilities as of September 2025: Skr12.50 Million SEK

Based on the latest financial reports, Active Biotech AB (ACTI) has total liabilities worth Skr12.50 Million SEK as of September 2025.

Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Active Biotech AB - Total Liabilities Trend (2000–2024)

This chart illustrates how Active Biotech AB's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.

Active Biotech AB Competitors by Total Liabilities

The table below lists competitors of Active Biotech AB ranked by their total liabilities.

Liability Composition Analysis (2000–2024)

This chart breaks down Active Biotech AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.17 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio 0.75 Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 2.78 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.74 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Active Biotech AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Active Biotech AB (2000–2024)

The table below shows the annual total liabilities of Active Biotech AB from 2000 to 2024.

Year Total Liabilities Change
2024-12-31 Skr11.13 Million -16.82%
2023-12-31 Skr13.38 Million -18.88%
2022-12-31 Skr16.49 Million +62.82%
2021-12-31 Skr10.13 Million +0.88%
2020-12-31 Skr10.04 Million -23.76%
2019-12-31 Skr13.17 Million -93.86%
2018-12-31 Skr214.52 Million -5.14%
2017-12-31 Skr226.14 Million -1.82%
2016-12-31 Skr230.32 Million -14.33%
2015-12-31 Skr268.84 Million -15.25%
2014-12-31 Skr317.21 Million -12.47%
2013-12-31 Skr362.40 Million +1.56%
2012-12-31 Skr356.82 Million +0.08%
2011-12-31 Skr356.53 Million +10.95%
2010-12-31 Skr321.34 Million +3.70%
2009-12-31 Skr309.86 Million +0.17%
2008-12-31 Skr309.34 Million +3.12%
2007-12-31 Skr299.97 Million -25.39%
2006-12-31 Skr402.04 Million +2.81%
2005-12-31 Skr391.05 Million +159.68%
2004-12-31 Skr150.59 Million +169.76%
2003-12-31 Skr55.82 Million -36.01%
2002-12-31 Skr87.24 Million +26.51%
2001-12-31 Skr68.96 Million -69.07%
2000-12-31 Skr222.92 Million --